HR+ Breast Cancer
7 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| (VELA) Study of BLU-222 in Advanced Solid Tumors (NCT05252416) | Blueprint Medicines Corporation | 2022-04-07 |
Track HR+ Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.